dipyridamole and roflumilast

dipyridamole has been researched along with roflumilast in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	2 (40.00)	2.80

Authors

Authors	Studies
Hughes, RA; Manallack, DT; Thompson, PE	1
Ashton, TD; Bland, ND; Campbell, RK; Cotter, K; Fang, AP; Gangurde, R; Garceau, N; Gechijian, L; Gustafson, AE; McAllister, G; Ochiana, SO; Ondrechen, MJ; Ortenberg, R; Pollastri, MP; Tallman, C; Wang, C; Wang, Z	1
Bankala, R; Doss, HM; Kapavarapu, RK; Kulkarni, P; Kumar, JS; Mathew, JE; Medishetti, R; Mudgal, J; Pal, M; Parsa, KVL; Ramarao, EVVS; Rasool, M; Shenoy, GG; Sunke, R; Thirupataiah, B	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Deng, J; He, X; He, YM; Huang, Y; Huang, YY; Liu, H; Luo, HB; Wang, Q; Xie, X; Yuan, Y; Zhu, J	1

Reviews

1 review(s) available for dipyridamole and roflumilast

Article	Year
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10 Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines	2005

Article

Year

The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.

Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10

Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines

2005

Other Studies

4 other study(ies) available for dipyridamole and roflumilast

Article	Year
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness. Journal of medicinal chemistry, 2011, Dec-08, Volume: 54, Issue:23 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Benzamides; Catalytic Domain; Humans; Models, Molecular; Molecular Structure; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African	2011
InCl European journal of medicinal chemistry, 2019, Jul-15, Volume: 174 Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Experimental; Freund's Adjuvant; Indium; Indoles; Molecular Structure; Multiple Sclerosis; Oligodendrocyte-Myelin Glycoprotein; Phosphodiesterase 4 Inhibitors; Quinoxalines; Rats; Structure-Activity Relationship; Zebrafish; Zebrafish Proteins	2019
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases. European journal of medicinal chemistry, 2022, Nov-15, Volume: 242 Topics: Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dextran Sulfate; Dipyridamole; Dogs; Inflammatory Bowel Diseases; Mice; Phosphodiesterase 4 Inhibitors	2022